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Abstract 
Recent evidences show that malignant cell undergo a metabolic reprogramming, acquiring new 
bioenergetic phenotypes. These new metabolic features grant them the capability of sustaining 
expensive processes such as cell growth and proliferation. Among the metabolic pathways 
involved, an increased glycolytic flux, the exploitation of alternative carbon source like 
glutamine, and an increase in fatty acid metabolism may be included. Metabolic reprogramming 
is strictly related to aberrant activation of signal transduction pathways, but the causal 
relationship between altered signalling and redesigned metabolism is currently under review, 
based on recent works showing a feedback mechanism, in which metabolites are involved in 
controlling signal fluxes through specific sensor kinases which monitor the cell bioenergetic 
status. Therefore, cancer cell metabolism represents a potential target for therapeutic 
intervention that may be integrated with conventional chemotherapy and molecularly targeted 
agents. In solid tumors, a great number of studies supports the potential of this  approach while 
only few are published in hematologic malignancies. 
With the aim of extending the knowledge of leukemia cell metabolic phenotypes, we studied the 
role of the main catabolic pathways, such as glycolysis, glutaminolysis and fatty acid oxidation.  
This study involved the use of metabolic inhibitors, in order to identify novel molecular 
therapeutic strategies in hematological malignancies. 
Dichloroacetate (DCA) is a pyruvate-mimetic molecule, which acts as pyruvate dehydrogenase 
kinase (PDHK) inhibitor, thus activating pyruvate dehydrogenase (PDH). This activation causes a 
shift in leukemic cell metabolism, from aerobic glycolysis to glucose oxidation. Our results 
documented that acute myeloid leukemia (AML) cells are characterized by higher rates of 
glycolysis compared to normal cells and that the use of DCA, an inhibitor of glycolysis, acts in a 
short time (30-60 minutes), increasing the levels of oxidative phosphorylation and, in a longer 
time, reducing cell growth and inducing apoptosis in cells of AML.  
Aminooxyacetic Acid (AOA) is a cellular transaminase inhibitor. This compound is able to inhibit 
the conversion from glutamate to α-ketoglutarate, second step of the glutaminolytic process. 
ST1326 is an aminocarnitine derivative, able to block the activity of CPT1a, the enzyme which 
catalyze the rate-limiting step of fatty acid oxidation. The results obtained in our in vitro study 
showed a high pro-apoptotic activity of this inhibitor in models of cell lines and primary cells 
from acute leukemia.  
Overall, these preclinical results demonstrate the role of cell metabolism as a potential 
therapeutic target in hematologic malignancies, warranting further extension of this strategy.   
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CHAPTER I 
Introduction 
 
1.1 Cancer cell metabolism: Introduction 
It is currently known that the transformation from normal to neoplastic cells (tumorigenesis) is 
the result of a multistep process that starts with the emergence of genetic alterations [1]. These 
changes involve the acquisition of several functional advantages, allowing cancer cells to survive, 
proliferate and disseminate within tissues and organs.  
In 2000 Hanahan and Weinberg observed that the vast repertoire of genetic alterations present 
in cancer cells is manifested through the acquisition of six major functional characteristics: 
independence from growth factors, insensitivity to anti-proliferative stimuli (e.g. contact 
inhibition), the ability to escape the mechanisms of programmed death (e.g. apoptosis), a 
practically unlimited replicative potential, increased angiogenesis, and the ability to invade and 
metastasize tissues [2].  
In more recent years, several authors have shown that many of the Signal Transduction 
Pathways (STPs) aberrantly activated in cancer cells actually converge on the deregulation of 
common metabolic mechanisms, responsible for cell growth and survival [3-6]. In light of these 
findings, it has been proposed that alterations in cellular metabolism are further distinctive 
feature of cancer [7].  
In neoplastic cells alterations of metabolic processes are necessary to fulfill three main basic 
needs: rapid production of ATP, an increased biosynthesis of macromolecules and an adequate 
cellular redox state [8]. To this end, tumors activate complex mutagenesis programs that induce 
drastic changes in levels and utilization of all biological macromolecules (carbohydrates, lipids, 
proteins, nucleic acids) [8]. The alterations of the metabolic processes, however, differ from 
tumor to tumor, because of the close interaction between the cells and the tumor 
microenvironment, where the concentrations of nutrients such as glucose and glutamine, or gas 
such as oxygen, are spatially and temporally heterogeneous [9].  
In recent years a large number of studies have focused on the analysis of metabolic aspects that 
distinguish cancer cells compared to normal counterpart, highlighting a central role for glycolytic 
and glutamine metabolism, not only in the maintenance of STPs but also, and above all, their 
direct contribution in the process of tumorigenesis [10]. 
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It is clear therefore that the study of metabolic changes that characterize neoplastic cells 
represent a very promising field of research for development of new therapeutic strategies 
capable of selectively targeting tumor cells [11]. The inhibition of metabolic processes, by 
blocking the catalytic activity of the enzymes involved, is configured as a strategy to reverse the 
neoplastic phenotype by inhibiting the growth, inducing apoptosis and inhibiting the 
neoangiogenic processes in invasive tumor cells [12].  
The most successful example of antineoplastic strategy based on metabolic therapies is certainly 
represented by the class of antifolate drugs [13], such as 5-fluorouracil, methotrexate, 
gemcitabine and fludarabine, widely used in the treatment of several cancers. Another example 
is represented by the use of L-asparaginase in the treatment of Acute Lymphoblastic Leukemia 
(ALL) [14] and lymphomas [15]. In more recent years, thanks to the elucidation of the molecular 
basis of metabolic reprogramming, it has been possible to define new therapeutic strategies 
based on the administration of glycolytic inhibitors [16], compounds capable of reducing the 
excess lactic acid produced by the tumor cells. However, other strategies can be adopted, 
focused on alternative carbon source, such as glutamine [17] and fatty acids [18].  
 
1.1.1 Glycolysis 
In the beginning of the last century, Warburg’s work demonstrated that cancer cells consume 
more glucose and generate more lactate when compared to normal cells. This lactic 
fermentation, distinctive of an anaerobic process, is independent from oxygen availability [19]. 
This anaerobic glycolysis upregulation, called “Warburg Effect”, has subsequently been 
confirmed in most cancer types [20], with few exceptions. Ramanathan and colleagues showed 
that the process of carcinogenesis increases cellular dependence on glycolytic, while decreasing 
its dependence on mitochondrial energy production [21]. By using a fibroblast model transfected 
with the telomerase catalytic subunit (hTERT) in combination with simian virus 40 large T antigen 
(LT), small T antigen (ST), and with an oncogenic allele of H-ras, and exposing these transfected 
fibroblasts to different metabolic inhibitors, they observed an increase in glycolysis inhibition 
sensitivity and a parallel loss in sensitivity to OXPHOS targeted agents, thus suggesting a shift 
from an oxidative to a more glycolytic metabolism during carcinogenesis [21].. 
For each glucose molecule the glycolytic process produces through lactic acid production 2 
molecules of ATP and re-generates redox intermediates: 2 NAD+ [22]. Conversely, the complete 
oxidation of glucose, though OXPHOS, has a theoretical yield of 38 ATP per molecule of glucose. 
This inefficiency in energy generation by cancer cells that appears as a paradox, given the high 
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energy demand, can be overcome by increasing the glycolytic flux: GLUT1 glucose transporter 
has been reported as overexpressed in a variety of tumors, such as bladder, lung, colon, breast, 
ovarian and gastric cancers [23]. Glycolytic enzymes, such as hexokinase, phopshofructokinase 
and pyruvate kinase, are as well upregulated in most cancer histotypes [24]. It has been 
suggested that, in non-limiting glucose condition, lactate production grants a higher energy yield 
compared to OXPHOS [25, 26].  Moreover, coupling glycolysis to ATP generation would leave 
Tricarboxylic Acid cycle (TCA) cycle intermediates available for incorporation in biosynthetic 
pathways, increasing the anaplerotic functions of the latter process.  
Furthermore, glucose itself can be used for biosynthesis of amino acids, lipids and nucleotides 
[27]. This observation is supported by data obtained by Nuclear Magnetic Resonance (NMR) 
focused on the carbon isotope 13 (13C), performed on glioblastoma cells, confirming Warburg 
effect and indicating that 10% of total glucose utilization is devolved to synthesis of fatty acids, 
amino acids and nucleotides [28]. In addition, the same work, along with others, underlines the 
importance of glutamine in tumor cell metabolism. 
1.1.2 Glutaminolysis 
Glutamine is a conditionally essential amino acid: normal cells are able to synthesize it, but in 
stress condition, such as sepsis, the increased demand is not met by biosynthesis [29]. Similarly 
to glucose, glutamine is fundamental in cancer cell metabolism. It acts as a carbon source, 
nitrogen donor, and as redox buffer, being the precursor of glutathione [30]. Glutamine 
catabolic process start with its deamination operated by the glutaminase enzyme, to form 
glutamate (Glu) and NH4. Glutamate is then converted by a deamination step to α-ketoglutarate 
(α-KG), a TCA cycle intermediate. The conversion of Glu to α-KG is catalyzed by Glu 
dehydrogenase or one of several transaminases, which convert α-keto acids into their 
corresponding amino acids [31].  Importantly, the flux of glutamine provide high rate of NADPH 
production used by cell for lipid and nucleotide biosynthesis [17].  
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Figure 1 – Metabolism of glutamine in cancer cells (from [32]) 
Thus, Glutamine can enter the TCA cycle directly (anaplerosis), or being diverted in peculiar 
series of reactions, termed reductive carboxilation: glutamine-derived α-ketoglutarate can be 
reductively converted into isocitrate, which is then isomerized to citrate to supply acetyl-CoA 
for de novo lipogenesis [33]. However, 13C tracking analysis on glioblastoma showed that 60% of 
glutamine is oxidized to lactate and alanine, while the remaining is used as an anaplerotic 
source, to replenish TCA cycle flux impaired by the diversion of glucose-derived pyruvate into 
lactic fermentation [28]. 
1.1.3 Fatty Acid Metabolism 
The metabolic reprogramming of cancer cells leads to a re-arrangement that involves also the 
third major carbon sink, fatty acids (FA). Similarly to glycolysis and glutaminolysis, it’s long 
known that cancer cells up-regulates the synthesis of these molecules [34]. Since these early 
observations, most groups focused their efforts on dissecting the de novo synthesis of FA (FAS), 
as a way for cancer cells to produce cell membranes, signaling lipid molecules, protein post-
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translational modifications and as energy supply to support rapid cell proliferation [35]. The 
overexpression of the Fatty Acid Synthase enzyme (FASN), the key enzyme of FAS, has been in 
fact reported in prostate, ovarian, breast, endometrial, thyroid, colorectal, bladder, lung, 
thyroid, oral, tongue, esophageal, hepatocellular, pancreatic and gastric carcinomas, malignant 
melanoma, mesothelioma, nephroblastoma and retinoblastoma, soft tissue sarcoma, 
gastrointestinal stromal tumor, Paget’s disease of the vulva and multiple myeloma (MM), as well 
as in some benign and pre-invasive lesions of prostate, breast, lung, stomach, colon and 
cutaneous nevi [36]. Interestingly, cancer cells prefer to synthesize new FA, instead of using 
available FA from bloodstream or from extracellular environment: Ookhtens and colleagues, 
using 14C labeled FA, demonstrated that 93% of FA is built de novo [37]. Moreover, a recent 
report from Scott and colleagues assessed the significant contribution of glutaminolysis, through 
the above mentioned process of reductive carboxilation, in providing the building blocks for FAS 
[38]. The established perturbations in FAS partially eclipsed the role of the oxidation process of 
these molecules (Fatty Acid Oxidation, FAO) in the bioenergetic balance of cancer cells, given 
that these two pathways are always been considerate as mutually exclusive. In fact, relatively 
few papers investigated FAO process in the tumor setting. However, a series of recent works 
focused on this process pinpointed the importance of FAO in supporting cancer cell survival and 
proliferation. Thompson’s group demonstrated that FAO can rescue cancer cells from glucose 
deprivation-induced apoptosis [39]. Nomura and colleague reported the overexpression of 
monoacylglycerol lipase (MAGL), a lipolytic enzyme that catalyzes the hydrolysis of 
monoacylglycerols, is highly expressed in aggressive tumors and controls the levels of free fatty 
acids (FFA) in cancer cells [40]. This mobilization of FA can then be exploited by tumor cell 
through β-oxidation. This process has been reported to be of high importance in glioblastoma 
[41, 42], prostate [43] and breast cancer [44]. Moreover, in breast cancer cells FAO appears to 
be activated by prolactin [45] and in recovering from stress conditions, such as loss of matrix 
attachment [46] and fluctuation of oxygen levels [47]. Combined, these evidences point thus 
toward a protective role for FAO in cancer cell metabolic stresses induced by microenvironment.  
 
1.2 Targeting Leukemia Cell Metabolism  
While in most solid tumors metabolism has been well characterized, few evidences have been 
reported on cell metabolism in hematological malignancies. However, in the last years the 
number of publications in this field increased. Results indicate that perturbations in metabolic 
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pathways are similar to what happen in solid tumors, paving the way for a therapeutic 
exploitation of these phenomena.  
1.2.1 Glycolysis 
Among the first metabolic alterations reported, an increase in glycolytic flux has been observed 
in leukemia cells. Using Akt-transfected immortalized hematopoietic cells, Thompson’s group 
demonstrated that Akt exerts a direct influence on glucose metabolism, inducing a dose-
dependent stimulation of glycolysis that correlates with a more aggressive phenotype [48]. The 
increase in glycolysis is not correlated to an increase in oxygen consumption rates, i.e. a 
complete glucose oxidation through the TCA cycle and OXPHOS, indicating that Akt hyper-
activation promotes the Warburg effect [48].  
An increased glycolytic flux has been then reported in Acute Lymphoblastic Leukemia (ALL) cells 
[49]. The gene expression profile of ALL blasts from newly diagnosed pediatric patients shows an 
up-regulation of genes related to glycolysis, and a down-regulation of genes related to TCA cycle, 
when compared to normal CD34+ [49]. Moreover, ALL blasts show a higher protein expression of 
GLUT-1 transporter [49]. Importantly, GLUT-1 appears to be fundamental in maintaining cell 
growth and apoptosis resistance in Bcr-Abl positive B-ALL [50]. Additionally, glycolysis rate has 
been strongly linked to chemotherapeutic drugs resistance in ALL [51-54]. 
Aberrant signaling by Bcr-Abl seems implicated in increasing the glycolytic flux in Chronic 
Myeloid Leukemia (CML) cells, via the PI3K-Akt axis [55], and higher glycolysis in CML cell lines is 
related to imatinib resistance [56].  
Evidences have been reported also in Acute Myeloid Leukemia (AML) cells. The aerobic glycolysis 
appears to be exacerbated in these cells by stromal interactions [57], and the extent of glycolytic 
flux seems to inversely correlate with patient prognosis [58]. More recently, Chen and colleague 
confirmed the enhanced glycolysis in AML cells, using mass spectrometry-based metabolomics 
[59]. In particular, they individuated a panel of 6 metabolites related to glucose metabolism 
(Lactate, 2-Oxo-glutarate, Pyruvate, 2-Hydroxy-Glutarate, Glycerol-3-phosphate, Citrate) having 
an independent prognostic value in cytogenetically normal AML patients [59].  
Perhaps the most convincing proof of the importance of aerobic glycolysis in leukemogenesis is 
presented in a very recent work by Wang and colleagues [60]. They used genetically modified 
murine models to investigate the effects of deletion in the two last enzymes of aerobic 
glycolysis, pyruvate kinase (PK) and lactate dehydrogenase (LDH), in normal hematopoietic stem 
cells and in normal murine BM cells transfected with either BCR-ABL or MLL-AF9 genes, in order 
to simulate a CML-like or an AML-like disease, respectively. After serial transplantations, they 
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observed that the conditional deletion of PK or LDH profoundly affected viability of leukemic-like 
cells, even following the first transplantation, while the effects on normal hematopoietic stem 
cells were detectable only after multiple transplants, thus individuating a “therapeutic window” 
for glycolysis interfering in leukemogenesis [60].  
Taken together, these results show that an increase in glycolytic flux is nearly universal in the 
different leukemia subtypes, pointing at the Warburg effect as a promising target for therapeutic 
intervention.    
Given that aerobic glycolysis is the best characterized metabolic alteration in leukemia cells, it is 
not surprising that the vast majority of metabolic inhibition attempts has been aimed at this 
pathway. The most used inhibitor has been 2-deoxyglucose (2-DG), a glucose analog that is 
phosphorylated by hexokinase but cannot be further processed, and accumulates in the cytosol 
inducing a decrease in ATP production, cell cycle blockage, inhibition of cell growth and 
apoptosis [61]. As single agent, 2DG proved effective in inducing apoptosis in ALL cells [49] and 
in suppressing xenotransplanted AML tumor growth [62]. 
However, being a glucose agonist, 2-DG is active only at high concentrations (millimolar range), 
difficultly achievable in patients due to serious side effects, such as induction of hyperglycemia 
[63]. Nonetheless, the use of 2-DG appear promising when used in combination therapy, 
showing a high degree of synergism with conventional chemotherapeutic agents, such as 
glucocorticoids in ALL [52], ATO [64] and AraC [59] in AML.  
 
Given the well-established impact of aberrant cell signaling on glycolytic flux, researchers 
focused on the possibility to target simultaneously the upstream kinase activity and the 
downstream effect on metabolism, in a two-level intervention aiming to overcome the 
resistance caused by bypassing mechanisms. Indeed, 2-DG is reported to sensitize leukemia cells 
to Bcl2 agonists [65, 66], Akt targeting agents [67] and death receptor activators [68, 69].  
Figure 2 – Chemical structure of 2-Deoxyglucose (from www.sigma-
aldrich.com) 
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The promising results obtained with 2-DG, together with its mentioned limitations, has led to the 
development of more potent glycolysis inhibitors, such as 3-bromopyruvate (3-BrPA) and its 
derivative, 3-bromo-2-oxopropionate-1-propyl ester (3-BrOP). 3-BrPA acts on Hexokinase, and it 
is reported to be effective in the micromolar range on AML cells, showing synergism with the 
main chemotherapeutic drugs [70, 71]. 
 
Figure 3 – Chemical structure of 3-bromopyruvate (from www.sigma-aldrich.com) 
 
However, authors reported an instability for this compound, that led to the generation of a more 
stable form, 3-BrOP. 3-BrOP is an ester of 3-BrPA, which can permeate cell membrane and 
undergoes hydrolyzation by cellular esterases, releasing the active moiety of the compound, the 
3-BrPA [72]. 3-BrOP has been reported to be more potent than its native form, inducing a 
reduction of cell proliferation in a panel of 15 different acute leukemia cell lines and primary 
blasts of myeloid and lymphoid origin, a drop in intracellular ATP levels and massive apoptosis; 
moreover, 3-BrOP showed high synergism when combined with an mTOR inhibitor, rapamycin 
[73]. 
1.2.2 Glutaminolysis 
It’s long known that leukemia cells, as solid tumors cells, require glutamine as substrate. Some 
hints derive from lesson learned from cell culture: without the addition of this amino acid, 
leukemia cells show impaired nucleotide synthesis [74], reduction of proliferation and of DMSO-
induced differentiation [75], decrease in ATP content [76], cell growth arrest and apoptosis [77]. 
Similarly to solid tumors, glutamine has been reported as anaplerotic substrate: diverting 
pyruvate into lactate, leukemia cells exploit glutamine to replenish TCA cycle and keep it active, 
in order to maintain the availability of this cycle intermediates for biosynthetic purposes [78].  
Glutamine addiction assumes a particular meaning in AML cells. In fact, mutation in metabolic 
genes has been recently reported in approximately 20% of AML [79]. In particular, using massive 
parallel genomic DNA sequencing, mutation in Isocitrate dehydrogenase (IDH) genes has been 
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found, with a peculiar association to cytogenetically normal patients. These genes encode for 
proteins involved in the TCA cycle, catalyzing the conversion from isocitrate to α-ketoglutarate 
[80]. Mutations in the active sites of these proteins leads to a gain of function: the enzymes 
catalyze an inverted reaction, starting from α-ketoglutarate to produce 2-hydroxy-glutarate 
(2HG). It is still unclear how this metabolite contributes to the carcinogenesis; however, 
evidences suggest that it can compete with α-ketoglutarate, blocking the activity of α-
ketoglutarate-dependent enzymes (i.e. dyoxigenases), or that 2HG can influence cellular 
epigenetic status interfering with histone demetylases, thus activating oncogenes or silencing 
tumor-suppressor [80]. 
 
 
The α-ketoglutarate used for 2HG production derives almost entirely from glutamine: through 
13C-labeled substrates and a liquid chromatography coupled to mass spectrometry (LC-MS) 
Figure 4 – Impact of 2-hydroxyglutarate on cellular processes (from [80]) 
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approach, Dang and colleague demonstrated that cells transfected with mutant IDH produces 
high level of 2HG, using the carbon skeleton from glutamine [81]. 
Glutamine antagonists exert cytotoxic effects on leukemia cells. Lyons and colleague showed in 
1990 that azaserine, acivicine and 6-diazo-5-oxo-L-norleucine block glutamine-dependent purine 
synthesis in murine leukemia cells, inbalancing the UTP/ATP ratio and causing accumulation of 
intermediate metabolites [82]. However, only recently additional reports underlined the 
promising effectiveness of targeting glutamine catabolism in leukemia cells.  
Bis-2-[5-(phenylacetamido)-1,3,4-thiadiazol-2-yl]ethylsulfide (BPTES) is a small molecule inhibitor 
that acts on glutaminase, the enzyme that catalyze the conversion from glutamine to glutamate, 
releasing ammonia ions [83]. This compound has been reported to be effective on Burkitt’s 
Lymphoma cells, reducing their proliferation in normoxic condition while inducing apoptosis in 
hypoxic condition [84]. Moreover, it significantly slows tumor progression in xenografted mice 
[84]. More recently, BPTES has been applied to primary AML cells with IDH mutation, since their 
mentioned reliance on glutamine [85]. The high sensitivity of IDH1 mutant cells to this 
compound [85] prompts further study on the therapeutic role of glutamine metabolism 
targeting in this particular subclass of patients. 
 
Figure 5 – Chemical structure of BPTES (from www.sigma-aldrich.com) 
 
1.2.3 L-asparagine 
Strictly biochemically related to glutamine, asparagine (Asn) is a non-essential amino acid. In the 
1960s, the activity of asparagine synthetase (ASNS), the enzyme responsible for its synthesis 
from aspartate and glutamine, has been found impaired in some leukemia subtype, especially in 
ALL [86]. This reduced activity cause a dependence of these cells from exogenous source of Asn, 
and this dependence has been promptly exploited as a therapeutic target: treatment with L-
asparaginase (L-ase) started in 1967, and since then L-ase has become of fundamental 
importance in childhood ALL treatment, inducing 40-60% of complete remissions as a single 
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agent, and nearly 95% of complete remissions when combined with vincristine and prednisone 
[88]. 
 
 
Figure 6 – E. coli L-asparaginase tetramer 
 
Interestingly, a debate is currently ongoing in the scientific community about the actual 
mechanism of action of L-ase, since this enzyme has also a glutaminase activity. While some 
authors attribute to this activity the insurgence of serious side-effects [89], prompting the 
development of new L-ases with undetectable glutaminase activity [90, 91], others suggest that 
the effectiveness of this therapy is also due to glutamine depletion [92, 93]. Recent studies 
support this latter hypothesis: using an LC-MS approach on adherent cells, Purwaha and 
colleagues showed that the induction of apoptosis by L-ase exposure is more related to 
glutamine levels than to asparagine concentration [94].  
Ehsanipur and colleagues reported that a possible resistance mechanism of ALL cells to L-ase 
may be caused by adipocytes releasing glutamine [95]. Bouscary’s group suggests that L-ase 
treatment may be useful in AML, since they reported mTORC1 inhibition, protein synthesis 
suppression and apoptosis induced by the glutaminase activity of L-ase in AML cell lines and 
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primary blasts [96]. A way to overcome resistance may be thus selecting for L-ases that can 
metabolize glutamine with higher affinity.  
 
1.2.4 Fatty Acid Metabolism 
While solid tumors often show an upregulation of FAS, evidences in leukemia for higher rates of 
this process are thus far very few. Some authors described an upregulation of FASN in AML [97, 
98], but the vast majority described a system in which both FAS and FAO works in a nearly 
physiological manner. An early report noted that leukemia cells tend to incorporate free fatty 
acids (FFAs) into phospholipids without altering them, while part of this FFAs are β-oxidized [99]. 
Importantly, nearly no carbon atoms from glucose are used by leukemia cells to de novo 
synthesis of lipids [99]. Supporting these observations, Skrede and Iversen reported an increase 
in oxidation and incorporation into phospholipids of labeled palmitate in a murine model of 
Acute Promyelocytic Leukemia (APL) [100]. More recently, two works from Nitta’s group 
suggested that, in some AML subtype, represented by THP-1 and HL60 cell lines, FAO can be 
important in replenish TCA cycle, providing the acetyl-CoA to feed this central metabolic hub 
[101, 102]. Taken together, these results suggest a higher rate of FA metabolism in leukemia 
cells, with a balance between oxidation and synthesis. In effect, some author suggested that to 
meet bioenergetic and biosynthetic needs of cancer cells, these two mutually exclusive 
processes can occur at the same time, by compartmentalizing them in two different cellular 
environment (namely cytosol for FAS, mitochondria for FAO) [103]. Alternatively, it can be 
speculated that leukemia cells alternate cycles of FAS and FAO, based on different time points in 
the cell cycle, in order to satisfy both the need for replenish TCA cycle and the demand for 
membrane phospholipids.  
Interfering with FA metabolism is a relatively new approach of targeting leukemia cell 
metabolism. As mentioned, the lack of extensive proofs on FAS leads researchers to focus on the 
β-oxidation process. Etomoxir is a well known FAO inhibitor: it blocks the import of FA in 
mitochondria, thus irreversibly inhibiting the first step of this process, catalyzed by carnitine-
palmitoyl-transferase 1 [104]. Samudio et al. in 2010 reported that etomoxir can reduce AML cell 
proliferation, alone or in co-culture with stromal cells; moreover, it synergizes with ABT-737 in 
apoptosis induction [105]. More recently, etomoxir has been shown to potentiate the apoptotic 
effects of ATO and glycolysis inhibitors, such as 2DG, on HL60 cell line [106]. 
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Figure 7 – Chemical structure of etomoxir (www.sigma-aldrich.com) 
 
Following studies on MM confirmed the effectiveness of etomoxir-induced FAO inhibition in 
hematological malignancies [107]. Interestingly, in the same study FAS inhibition by orlistat 
seems to induce apoptosis as well [107], thus indicating that the whole machinery involved in FA 
can be a promising therapeutic target.  
1.2.5 Pentose Phosphate Pathway 
Early observations by Lengle and colleagues reported that pentose phosphate shunt (PPP) is 
upregulated in leukemic cells from a murine model [108]. However, authors concluded that, 
whether the flux was higher, the percentage of glucose metabolized by this pathway was 
comparable to that of normal thymocytes [108].  This high flux through the non-oxidative branch 
of PPP has been confirmed in Jurkat cells through 13C-NMR analysis: labeled glucose is partially 
diverted in PPP and metabolized for de novo synthesis of ribose-5-phosphate, an essential 
precursor of nucleotides [109]. Chemoresistance has been linked to high flux in PPP [110] and to 
overexpression of glucose-6-phosphate dehydrogenase, the key enzyme of this process [111]. 
Moreover, a recent report from Yamamoto and colleague showed an upregulation of PPP flux in 
U937 cell line when exposed to oxidative stress, and a concomitant reduction in glycolytic flux 
mediated by methylation of phopshofructokinase/fructose bisphosphatase 3 [112]. Some 
evidence of a hyperactivity of 6-phoshogluconate dehydrogenase, involved in the oxidative 
branch of PPP, has been reported in leukemia blasts [113], indicating that both the oxidative and 
non-oxidative branches of PPP may represent a potential target.  
The effect of 6-Aminonicotinamide (6-AN), a 6-phoshogluconate dehydrogenase inhibitor, has 
been extensively investigated, showing a cytotoxic effect as single agent [114] and a sensitizing 
action when used in combination with chemotherapeutic drugs [115, 116]. Furthermore, 6-AN is 
reported to synergize with the Bcl2 inhibitor ABT-263 in inducing apoptosis in leukemia cells 
[117]. Additional studies are needed to fully explore the potentiality behind PPP interfering.  
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Figure 8 – Chemical structure of 6-Aminonicotinamide (from www.caymanchem.com) 
 
1.2.6  Oxidative Phosphorylation (OXPHOS) 
Recently, alterations of mitochondrial gene expression have been reported in CML stem cells. In 
particular, an upregulation of genes encoding for complex I, II, IV and V, and a deregulation of 
complex III gene transcription [118] which the authors correlated with the high amount of ROS 
usually found in those cell has been reported [119]. Several groups detected mutations on 
mitochondrial DNA in genes coding for complex I [120, 121], and complex IV [122] in AML 
patients. Although these studies lack of extensive functional characterizations, their results may 
partially explain the dependence of leukemic cells from glycolysis, at least in some subgroups.  
On the contrary, different evidences are emerging about Chronic Lymphoblastic Leukemia (CLL) 
cell metabolism, as these cells seem to rely more on oxidative phosphorylation than glycolysis. 
Jitschin and colleagues observed in CLL cells high levels of ROS derived by an enhancement in 
OXPHOS, caused by higher functional mitochondria biogenesis and increased respiratory rates 
[123]. If confirmed, these results place CLL in a different metabolic category compared to the 
other hematological malignancies, as these cells are not subjected to the Warburg effect. 
The upregulation of glycolysis, and the diversion of pyruvate into lactate, does not completely 
shut down the OXPHOS. Thus, mitochondrial respiration could be a reliable target. Since the 
appearance of a report, observing a reduced incidence of cancer in metformin-treated diabetic 
patient [124], this molecule has been extensively studied as anti-neoplastic agent. Metformin is 
a biguanide derivative with a double action: it inactivates mTORC, through an AMPK dependent 
mechanism, and inhibits electron transfer chain complex I [125].  
19 
 
 
Figure 9 – Chemical structure of Metformin (from www.stressmarq.com) 
 
This molecule appear to be effective in induce reduction of cell proliferation and apoptosis in 
CML [126], AML [127, 128] and ALL [126, 129, 130]. However, it is still unclear if metformin 
exerts its pro-apoptotic action through the mTORC inhibition or its effect on cell metabolism, 
prompting further study to understand and enhance its properties.  
 
1.3 Traditional and Novel Technologies for Studying Cell Metabolism in 
Hematological Malignancies 
Cell metabolism has been investigated through a variety of instrumentation, from Clarke-type 
oxygen sensor to measure oxygen consumption, to spectrophotometric detection of metabolites 
through generation of fluorescent intermediates. However, three are the current technologies 
that allow the most comprehensive view of cell metabolism. While Nuclear Magnetic Resonance 
(NMR) and Mass Spectrometry (MS) are nowadays well established and widespread, Seahorse 
XF Analyzer is rapidly expanding as a cost-effective way to monitor in real-time metabolic rates 
of live intact cells. 
NMR exploits nuclear spin of magnetic-field immersed atom nuclei: the emission of 
radiofrequencies allows to interact and detect specific atom groups, distinguishing up to 75 
metabolites in a sample, with a sensitivity lower limit around 5µM [131].  
Mass spectrometry is based on fragmentation of molecules and their separation based on 
mass/charge ratio. Typically, to increase resolution power, MS is coupled to purification system, 
such as liquid chromatography (LC) [132]. Combining these two technologies, LC-MS is able to 
identify from 200 to 500 metabolites, with a limit of detection in the picomolar order [131]. 
Usually, there are two kind of strategies related to both types of technology: an untargeted 
approach, aimed at the detection of all possible metabolites and in putative differences in 
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metabolite distributions between paired samples (i.e. normal vs. cancer, control vs. treated, 
time-series), and a targeted approach, in order to detect specific pathways and to quantify their 
fluxes [133]. Both these technology have been successfully applied to the biological 
characterization of hematological malignancies: NMR metabolomics on patient sera proved 
effective in distinguish between IGHV-mutated and unmutated in early-stage untreated CLL 
patients [134], while MS-based metabolomics has been able to show that glucocorticoids act by 
inhibiting glucose metabolism in ALL cells [53]. An untargeted approach, and a combination of 
NMR and MS, has been adopted by Tiziani and colleagues to detect differences between the 
bone marrow and peripheral blood compartments in pediatric ALL primary blast metabolism as 
well as the metabolic response to L-ase treatment, confirming high rates of aerobic glycolysis in 
these cells and that L-ase partially acts by depleting glutamine pool [135].  
However, the main limitation of NMR and MS is the need for a metabolite extraction, which 
means that cells have to be destroyed in order to perform experiments. 
On the other hand, Seahorse XF Analyzer is a new instrument able to simultaneously measure, in 
real time and on live cells, extracellular acidification rate (ECAR) and oxygen consumption rate 
(OCR). ECAR is proportional to lactate derived from glycolysis and excreted by cells in the 
extracellular medium [136]. OCR is proportional to mitochondrial respiration, and thus to 
OXPHOS [136]. The presence of drug injection ports (4 per well) allows to interact with cell 
metabolism, adding specific inhibitors to further dissect metabolic fluxes, or investigating 
metabolic response to a specific drug.   
A typical XF experiment proceeds through a seeding phase, where cells are moved in the special 
multiwell designed for the XF; a switch in culture medium, replacing it with a non-buffered 
medium, in order to allow the acidification rate measurement; loading of chosen compound in 
the drug injection ports; calibration of XF fluorimetric sensors. Once started, the XF measures 
OCR and ECAR for about 120 minutes.  
To measure glycolysis rate, only glutamine is added to the assay medium. The first three round 
of measurement gives the basal state. The first injection is composed of glucose 10mM, followed 
by 3 rounds of measurements to detect glycolytic rates. Measurements following injection of 
oligomycin A, an ATP-synthase inhibitor that shuts down mitochondrial energy production, 
reveal the maximal glycolytic rates. Finally, 2-DG is injected to block glycolysis and detect the 
lactate-independent acidification, to be subtracted during data processing. Fig 10 shows a 
representative glycolysis experiment on the XF analyzer. 
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Figure 10 – Typical experiment to measure cellular glycolytic capacity (from www.seahorsebio.com) 
For mitochondrial respiration experiments, the assay medium is supplemented with glucose, 
pyruvate and glutamine. As for the measurement of glycolysis rate, the first three rounds of 
measurements give the basal respiration rate. Injection of oligomycin A and following 
measurements reveal the portion of oxygen consumption coupled to ATP synthesis. Then, the 
injection of FCCP, an agent that discharge the across membrane electrochemical gradient, allow 
the detection of maximal respiration rates. Finally, a mixture of complex I and complex III 
inhibitors, rotenone and antimycin respectively, completely shuts down the electron transfer 
chain and reveals the non-mitochondrial oxygen consumption. Fig 11 shows a representative 
mitochondrial respiration experiment with the XF analyzer. 
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Figure 11 – Typical experiment to measure cellular mitochondrial respiration (from 
www.seahorsebio.com) 
 
By varying substrate composition in assay medium, it is possible to investigate the various 
contribution of each substrate to cell metabolism. For example, in order to study FAO the assay 
medium is supplemented with BSA-conjugated palmitate and L-carnitine [137]. The 
mitochondrial respiration experiment, conducted in this assay buffer, reveals the oxygen 
consumption only due to β-oxidation. In the same way, it is possible to measure glutamine 
contribution to cellular metabolism. 
Seahorse XF analyzer has already been successfully applied in hematological malignancies, to 
investigate metabolic dependence [123, 138, 139] and in drug discovery [140-142] 
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1.4 Aim of the study 
 
In recent decades a large number of studies have shown that genetic alterations acquired by 
tumors deeply reprogram basal metabolism, allowing these cells to acquire proliferative 
advantages, combining the energy demands of growth with the biosynthetic needs imposed by 
proliferation, and to significantly increase the cell survival even in adverse environmental 
conditions. 
Initially described by the German scientist Otto Warburg, these alterations in cancer cells induce 
a purely glycolytic metabolic phenotype through increasing at both transcriptional and protein 
level the expression and the activity of enzymes involved in the glucose catabolism. At the same 
time, this metabolic program is able to strongly reduce the oxidative processes of tumor cells 
deflecting the normal carbon fluxes from the catabolic pathways to those biosynthetic. This 
effect appears as a result of the reduction of the expression and/or activity of mitochondrial 
enzymes, or following the expression of specific isoforms, differently regulated than those 
expressed in healthy cells. In addition, in certain tumor contexts amino acids such as glutamine 
or lipids such as FA are metabolized intensively for energetic and biosynthetic purposes, thus 
participating in the growth, proliferation and survival of cancer cells. In other tumor models (e.g. 
breast cancer, pancreatic tumors, glioblastoma, and acute leukemias) the metabolic program 
described above is associated with the use of β-oxidation process for energy purposes. The fatty 
acid oxidation in these cells may in fact represent an alternative source of carbon, capable of 
maintaining the Krebs cycle and other mitochondrial oxidative metabolism fully functional. 
Thus, the purpose of this work is to investigate the therapeutic potential of a metabolism-
targeted approach, aimed at the three main catabolic pathways (glycolysis, glutaminolysis, and 
fatty acid oxidation) in leukemia models.  
To this end we evaluated the effect of three specific inhibitors: i) Dichloroacetate, an agent able 
to reverse the Warburg effect and restore an oxidative phenotype; ii) Aminooxyacetate, a 
transaminase inhibitor that interfere with the glutaminolytic process; iii) ST1326, a FAO inhibitor 
that selectively and reversibly targets CPT1a, the key enzyme of this process. 
The effects induced by the aforementioned compounds have been investigated with both 
traditional/functional approach (cell counts, flow cytometry) and cutting-edge technology 
(Seahorse XF Analyzer), in order to elucidate the mechanisms behind the action of these 
metabolic inhibitors on cell lines and primary samples from hematological malignancies. 
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Chapter II 
Targeting glycolysis in AML cells: Dichloroacetate 
 
2.1 Introduction 
As reported by Chen and colleagues, AML cells actively uses aerobic glycolysis in order to 
produce the energy needed for survival and proliferation [59]. Thus, we chose to target this 
process with a metabolic modulator, the dichloroacetate (DCA). 
 
 
Fig 12 – Chemical structure of DCA (from [143]) 
 
DCA is a pyruvate-mimetic molecule, which acts as pyruvate dehydrogenase kinase (PDHK) 
inhibitor, thus activating pyruvate dehydrogenase (PDH) [144]. DCA binds a site located in the N-
terminal domain of PDHK, promoting a conformational change that inactivates this kinase 
[143].Thus, pyruvate derived from glucose catabolism is no longer diverted towards lactic acid 
generation, but it’s re-directed toward complete oxidation in mitochondrial TCA cycle. The net 
effect is the reversal of the Warburg effect, and a modulation of cell metabolism to adopt a 
more oxidative phenotype (fig. 13). 
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Figure 13 – DCA mechanism of action and metabolic repercussions (from [145]) 
 
For its action, dichloroacetate has been used to treat lactic acidosis in children [146], generally 
demonstrating a good tolerability and safety [147]. 
In the attempt to reverse Warburg effect, in 2007 Michelakis and colleagues reported that DCA 
induces a mitochondrial-dependent apoptosis in cancer cells [148]. Since then, DCA has been 
investigated in cancers with different origins: the anti-neoplastic effects of this molecule as 
single agent have been reported in glioblastoma [149], metastatic breast [150], endometrial 
[151], colorectal [152] and ovarian cancers [153]. Additionally, DCA has been shown to synergize 
with conventional chemotherapy [154-156] and with metformin [157, 158]. 
In hematological malignancies, the pro-apoptotic activity of DCA has been demonstrated in T-
cell lymphoma [159], MM [160] and in chronic lymphocytic leukemia [161]. 
Chen and colleagues reported a DCA-induced apoptosis in a small panel of cell lines and in 3 
primary samples of AML [59]. 
Here, we extend these observations, evaluating the effects of cell metabolism modulation, by 
DCA exposure, on a larger panel of AML cell lines and primary samples. 
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2.2 Materials 
2.2.1 Reagents 
DCA was purchased from Sigma-Aldrich (Gillingham, UK) and stored at +4°C until use.   
 
2.2.2 Cell culture and primary samples 
AML cell lines (HL60, KG1, MOLM-13, OCI-AML2, OCI-AML3, U937) were cultured under standard 
conditions (37°C in 5% CO2 humidified atmosphere), were harvested in log-phase growth for all 
experiments, and exposed for 24, 48, 72 hours to scalar concentrations of DCA (1 to 7.5mM). 
Normal mononuclear cells were obtained from peripheral blood (NPBLs) samples of volunteer 
donors. PB and/or bone marrow (BM) aspirates samples were obtained from 8 AML patients 
(Table 2), who provided written informed consent, in accordance with regulations and protocols 
sanctioned by the Human Subjects Committee of Helsinki and approved by the Institutional 
Review Board of the Sapienza University of Rome. Cells were suspended in complete medium to 
a starting concentration of 1.0x106/mL and exposed to scalar concentration of DCA (1 to 
7.5mM). 
Following DCA exposure, cell lines and primary cells were evaluated for cell counts, viability, 
induction of apoptosis and ROS production  
 
2.3 Methods  
2.3.1 Apoptosis analysis 
Induction of apoptosis was assessed by measuring Annexin V binding to externalized 
phosphatidylserine, as previously described. Briefly, cells were washed twice with PBS and 
resuspended in binding buffer (10 mM Hepes/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2, Sigma 
Chemical Co.). FITC conjugated Annexin V (Roche Diagnostic Corp., Indianapolis, Indiana, USA) 
was added at a final concentration of 1μg/ml. The mixture was incubated at room temperature 
for 15 min in the dark prior to flow cytometry analysis. Membrane integrity was simultaneously 
assessed by PI (0.25μg/ml) exclusion.  
2.3.2 ROS production 
For the analysis of ROS content, cells were incubated with 4 µM dihydroethidium (DHE; 
Molecular Probes, Eugene, OR) for 15 minutes at 37°C. After incubation, the cells were analyzed 
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by flow cytometry. ROS production was evaluated at different time points after treatment, as 
indicated.  
2.3.3 Real-time Metabolic Analysis 
Basal and DCA-affected glycolytic and mitochondrial metabolism were measured by Seahorse 
XF24 Analyzer (Seahorse Bioscience, MA, USA). Briefly, XF24 plates were coated with Celltak (BD 
Bioscience) to ensure cell adherence, following manufacturer’s protocol. Cells were moved into 
minimal DMEM assay medium (Seahorse Bioscience, MA, USA), with no glucose, no glutamine, 
no phosphate buffer, added with 2mM glutamine (Euroclone, Milan, Italy) and adjusted to pH 
7.35, then transferred in XF microplates (500k cells per well). Microplates were briefly 
centrifuged (1000 rpm, 5’) and then transferred in a CO2-free incubator.  
For glycolysis rate experiments, drug injector ports in the disposable sensor-containing cartridge 
were loaded with glucose 100mM (Sigma Aldrich), dissolved in the assay medium, adjusted to 
pH 7.35, for a final concentration in the well of 10mM, in port A. Port B were loaded with 
oligomycin (Seahorse Bioscience, MA, USA), dissolved in assay medium, at concentration of 
10µM, for a final concentration in the well of 1µM. Port C were loaded with 2-DG 1M (Seahorse 
Bioscience, MA, USA), dissolved in assay medium, adjusted to pH 7.35, for a final concentration 
in the well of 100mM. After a 30’ equilibration in a CO2-free incubator, cartridges were inserted 
into the XF analyzer for the calibration step. After calibration, cell-containing plates were moved 
in the XF analyzer. The experiments were composed of: a) three cycles of measurements,  b) 
injection of glucose (port A), c) three cycles of measurements, d) injection of oligomycin (port B), 
e) 3 cycles of measurements, f) injection of 2-DG (port C), g) 3 cycles of measurements. 
For DCA experiments, drug injector ports in the disposable sensor-containing cartridge were 
loaded with glucose 100mM (Sigma Aldrich), dissolved in the assay medium, adjusted to pH 
7.35, for a final concentration in the well of 10mM, in port A. Port B were loaded with DCA, 
dissolved in assay medium, adjusted to pH 7.35, at concentration of 50 and 100mM, for a final 
concentration in the well of 5 and 10mM, respectively. After a 30’ equilibration in a CO2-free 
incubator, cartridges were inserted into the XF analyzer for the calibration step. After 
calibration, cell-containing plates were moved in the XF analyzer. The experiments were 
composed of: a) three cycles of measurements, b) injection of glucose (port A), c) three cycles of 
measurements, d) injection of DCA or vehicle (port B), e) 6 cycles of measurements. 
For mitochondrial repiration experiments, drug injector ports in the disposable sensor-
containing cartridge were loaded with oligomycin 10µM (Sigma Aldrich), dissolved in the assay 
medium, adjusted to pH 7.35, for a final concentration in the well of 1µM, in port A. Port B were 
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loaded with FCCP 2µM, dissolved in assay medium, adjusted to pH 7.35, for a final concentration 
in the well of 0.2µM. Port C were loaded with Antimycin A (10µM) and Rotenone (10µM), 
dissolved in assay medium, adjusted to pH 7.35, for a final concentration in the well of 1µM for 
both compounds. After a 30’ equilibration in a CO2-free incubator, cartridges were inserted into 
the XF analyzer for the calibration step. After calibration, cell-containing plates were moved in 
the XF analyzer. The experiments were composed of: a) three cycles of measurements,  b) 
injection of Oligomycin (port A), c) three cycles of measurements, d) injection of FCCP (port B), e) 
3 cycles of measurements, f) injection of Antimycin and Rotenone (port C), g) 3 cycles of 
measurements. Cell viability after XF experiments were assessed by Trypan Blue exclusion. 
When needed, data from XF analyzer were normalized for cell counts. 
2.3.4 Data analysis and statistics 
For all in vitro results, at least three independent experiments were performed to determine 
mean and SD values. IC50s were calculated using the CalcuSyn software (Biosoft, Cambridge, 
MA) based on the number of Annexin V positive cells at 72h. Statistical comparisons were 
performed using the paired Student’s t test. 
2.4 Results & Discussion 
First, we investigated the glucose metabolism in AML cell lines, by using the XF Analyzer. All cell 
lines tested showed remarkably higher rate of lactate excretion than NPBLs: for example, 
MOLM13 showed a 4.6 fold increase in glycolytic rates when compared to NPBLs [18.9±2.6 vs. 
4.1±0.2 (mpH/min) 106cells, respectively, p<0.001] (fig 14).  
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Figure 14 – AML cell line show higher rate of glutaminolysis compared to NPBLs. Glycolytic levels of 
NPBLs and Molm13 were determined in real time with the Seahorse XF analyzer, as indicated in the 
method section. 
Then, we assessed DCA effects on leukemia cell metabolism. The injection of DCA (5mM, fig.16) 
on U937 cells caused a temporary dose-dependent drop in lactate production (-36.5%, 
p=0.0014, compared to vehicle), followed by a rapid recovery in ECAR value, returning to control 
levels after 30 minutes of exposure (fig. 15a). On the other hand, mitochondrial respiration was 
positively affected: DCA induced an increase in O2 consumption (45%, p=0.014, compared to 
vehicle) (fig. 15b). These enhanced mitochondrial respiration remained stable throughout the 
entire experiments (120 mins).  
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Figure 15 – DCA induces a metabolic shift in AML cells. Real time metabolic measurement was conducted 
on U937, as described in the method section. Data from the same experiment show: a) glycolytic rate and 
b) mitochondrial respiration rate, obtained by the Seahorse XF analyzer, before and after the injection of 
glucose and DCA. 
 
 
To confirm this mitochondrial metabolism enhancement, we evaluated the effects on 
mitochondrial respiration after 1 hour of DCA (10mM) exposure, compared to glycolysis inhibitor 
2DG (10mM) (fig.17). As mentioned, 2-DG is a “canonical” glycolysis inhibitor, a glucose analog 
that cannot be metabolized, blocking the activity of hexokinase. The comparison has been made 
to exclude a compensatory effect, i.e. an upregulation of oxidative phosphorylation to face the 
reduced energy income from glycolysis. Indeed, 2DG showed little activity on mitochondrial 
metabolism, indicating that AML cells do not compensate a reduced glycolysis with an increased 
OXPHOS. On the contrary, DCA was able to significantly enhance both basal and maximal 
respiration rate (measured after the injection of an electron chain accelerator, FCCP) (fig. 16). 
These data are in line with the reported DCA mode of action [144], with a shift toward a more 
oxidative and less glycolytic metabolism by cells when exposed to this molecule. 
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Figure 16 – DCA mediates a reversal of Warburg effect. U937 cell lines were exposed for 1h to DCA or 
2DG. Mitochondrial respiration was measured through the Seahorse XF Analyzer, as described in the 
methods section. 
 
We then tested the long-term effects of DCA exposure on AML cell lines (HL60, KG1, MOLM-13, 
OCI-AML2, OCI-AML3, U937). In all lines, DCA induced a reduction of cell growth in a dose- and 
time-dependent fashion, as indicated in fig 17.  
Cell growth reduction was associated with apoptosis, as confirmed by Annexin V analysis (fig 18). 
While U937 appeared to be the most sensitive (72h IC50=2.62mM), two cell lines, HL60 and OCI-
AML2, proved resistant to this compound (table 1). 
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Figure 17 - DCA induces a reduction in AML cell proliferation: MOLM13 (a) and HL60 (b) cell line were 
exposed to the indicated concentrations of DCA. Cell counts and viability were assessed at the times 
indicated by Trypan blue exclusion counting. 
 
Figure 18 – DCA exerts a dose- and time-dependent pro-apoptotic effect on AML cell lines. MOLM13 (a) 
and HL60 (b) cells were exposed to the indicated concentrations of DCA. Apoptosis induction was assessed 
by Annexin V/PI staining (see “Material and Methods” section). Percentage of Annexin V positive cells are 
shown in the figure. 
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Table 1 – DCA induces apoptosis in AML cell lines. IC50 was calculated after 72h of DCA exposure 
 
We found no correlation between basal cell line glycolytic rates and DCA sensitivity (fig 19). 
Thus, we suggest that this heterogeneous effect may be probably related to an inability by the 
sensitive cell lines to cope with the shift toward a more oxidative metabolism. 
 
 
Figure 19 – DCA effect has no correlation with the glycolytic rate. Maximal glycolytic rates of AML cell 
line panel were measured by Seahorse XF Analyzer as described in the method section. 
 
It has been suggested that DCA exerts pro-apoptotic effect through ROS accumulation [162, 
163]. To confirm this evidences, we evaluated ROS production in cell lines after 24h of DCA (1-
7.5mM) exposure by DHE staining. At 24h, percentage of DHE-positive U937 cells exposed to 
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DCA increased from 9.2±1.7% (vehicle) to 12.6±0.5% (1mM, p=0.002), 20.3±4.5% (2.5mM, 
p=0.043), 30.2±5.2% (5mM, p=0.018) and 39.6±4.7% (7.5mM, p=0.011) (fig. 20). This observation 
partially supports our hypothesis of a leukemia cell subset that cannot sustain high rate of 
oxidative phosphorylation.  
 
Figure 20 – DCA acts through a dose-dependent ROS over-production. U937 were grown in the absence 
or presence of scalar concentrations of DCA for 24h. ROS levels were determined at 24h by monitoring 
DHE uptake (see methods). 
 
DCA is reported to be well tolerated in subjects with metabolic diseases, even in long-term 
administration [164]. In order to confirm DCA safety on our normal controls, we exposed NPBLs 
to DCA 5 and 7.5mM for up to 72h. No significant effects were observed on both normal and 
activated NPBLs: at 72h, Annexin V positive cells ranged from 26.2±11.9% (vehicle), to 27.8±7% 
(5mM) and 35,5±5,3% (7.5mM) for NPBLs (p>0.05) (suppl.fig.2a); and from 57±6.7% (vehicle), to 
59.1±3.8% (5mM) and 64.4±3.8% (7.5mM) for PHA-activated NPBLs (p>0.05) (Fig. 21a,b).  
 
Vehicle 1mM 2.5mM 
7.5mM 5mM 
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Figure 21 – DCA has no effects on NPBLs. Normal (a) and activated (b) NPBLs were incubated with DCA for 
up to 72 hours. Apoptosis induction was assessed by Annexin V/PI staining (see “Material and Methods” 
section). Percentage of Annexin V-positive cells is shown in the figure. 
 
Finally, we investigated the effects of DCA exposure (1-7.5mM) on primary blasts from 8 patients 
(table 2). Cell growth reduction and induction of apoptosis were observed: after 72h of exposure 
to scalar concentration of DCA, Annexin V positive cells ranged from 21.1±9.4% (vehicle) to 
33.6%±15,3% (1mM, p=0.044), 44.9±19,9% (2,5mM, p=0.0046), 61.2±25.7% (5mM, p<0.001), 
69.7±19.1% (7,5mM, p<0.001) (fig.22). 
pt #  Sex  BM Blasts (%)  FAB  
1  F  100  -  
2  M  90  M1/M2  
3  M  80  M1  
4  M  64  M2  
5  M  99  M2  
6  F  90  M5  
7  M  90  M5  
8  F  100  M1  
 
Table 2 – Patient Population 
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Figure 22 – DCA induces a dose-dependent apoptosis in AML primary cells. AML primary cells were 
exposed to the indicated concentrations of DCA for 72h. Apoptosis induction was assessed by Annexin 
V/PI staining (see Methods section). Percentage of Annexin V-positive cells is shown in the figure. 
 
In agreement with results obtained by Chen and colleagues [59] indicating a DCA-induced anti-
neoplastic effect in AML cells, our analysis confirm the effectiveness of this agent in inducing cell 
growth reduction and apoptosis induction on these cells. Moreover, concentrations used were 
sufficient to modulate cellular glycolysis in our model, forcing leukemic cells to adopt a more 
oxidative metabolism. The shift to the oxidative phenotype is not sustainable by these cells, as 
suggested by the accumulation of intracellular ROS briefly after DCA exposure. Thus, together 
with results obtained in MM and CLL [160, 161], these evidences underline the promising role 
for DCA in modulating cell metabolism in hematologic malignancies, prompting further studies 
about its possible clinical role in conjunction with standard chemotherapy. 
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Chapter III 
Targeting glutaminolysis in AML cells: Aminooxyacetate 
 
3.1 Introduction 
Glutamine deprivation has been demonstrated to induce cell growth reduction and apoptosis on 
AML cells. Thus, we targeted this process, by using a chemical inhibitor of cellular transaminases, 
Aminooxyacetic Acid (AOA) [165]. Among this class of enzymes, glutamate-dependent 
transaminases contribute to glutaminolysis by converting glutamate into the TCA cycle 
intermediate α-ketoglutarate [166]. 
 
Figure 23 – Chemical structure of AOA (from www.sigma-aldrich.com) 
 
AOA proved particularly effective in inhibiting glutaminolysis, as shown by Wise and colleagues 
in an important work about the role of c-Myc in driving glutamine catabolism in cancer cells 
[167]. Using c-Myc transfected fibroblast, they demonstrated that AOA is able to selectively 
induce apoptosis in glutamine-addicted Myc-expressing cells [167]. To further demonstrate AOA 
specificity, they observed that the addition of α-ketoglutarate, the final product of glutamate-
dependent transaminases, fully prevented AOA-induced apoptosis [167].  
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Figure 24 - AOA inhibition of glutaminolysis 
 
Thornburg and colleagues reported an AOA-induced reduction of cell proliferation, in cell lines 
and in xenograft murine models of breast cancer, through mitochondrial metabolism 
impairment [168]. Moreover, Qin and colleagues reported a sensitivity of melanoma cells to 
AOA, particularly when combined with death receptor ligands [169]. Additionally, a similar AOA 
pro-apoptotic activity, through reduction of cellular respiration, has been reported in 
osteosarcoma [170].  
These results, along with the pronounced glutamine addiction of cancer cells, prompted us to 
investigate the effect of glutaminolysis inhibition, by AOA exposure, in AML cells. 
 
3.2 Materials 
3.2.1 Reagents 
AOA was purchased from Sigma-Aldrich (Gillingham, UK). The compound was stored as dry 
powder at 0-4°C and dissolved in PBS immediately before use. 
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3.2.2 Cell culture and primary samples 
AML cell lines (HL60, MOLM-13, OCI-AML2, OCI-AML3, U937) were cultured under standard 
conditions (37°C in 5% CO2 humidified atmosphere), were harvested in log-phase growth for all 
experiments, and exposed for 24, 48, 72 hours to scalar concentrations of AOA (from 100 to 
1000µM). 
Normal mononuclear cells were obtained from peripheral blood (NPBLs) samples of volunteer 
donors. PB and/or bone marrow (BM) aspirates samples were obtained from 8 AML patients 
(Table 2), who provided written informed consent, in accordance with regulations and protocols 
sanctioned by the Human Subjects Committee of Helsinki and approved by the Institutional 
Review Board of the Sapienza University of Rome. Cells were suspended in complete medium to 
a starting concentration of 1.0x106/mL and exposed to scalar concentration of AOA (100 to 
1000µM). 
Following AOA exposure, cell lines and primary cells were evaluated for cell counts, viability, and 
induction of apoptosis as reported in Chapter II. 
 
3.3 Methods 
3.3.1 Glutaminolytic Rates 
Ammonia is the byproduct of the transamination reaction that converts glutamate in α-
ketoglutarate. Once produced, it is rapidly excreted in the extracellular environment [28]. 
Glutaminolysis rates in cell lines and NPBLs, resting or PHA-activated, were detected by 
measuring ammonia levels in culture medium, as reported in literature [101]. Briefly, cells were 
centrifuged (1200 rpm, 5’), the supernatant were collected, and stored at -20°C until analysis. 
Ammonia levels were measured through Ammonia Colorimetric Assay Kit (Biovision, CA, USA), 
following manufacturer’s instruction. 
 
3.4 Results & Discussion 
First, we measured glutaminolytic rates of AML cell lines, compared to NPBLs. After 24h, the 
ammonia level in cell line medium were significantly (p<0.05) higher than both normal and 
activated NPBLs (fig.25): OCI-AML3 excreted 3 times more ammonia compared to normal NPBLs 
(p=0.02), thus confirming a sustained glutaminolytic rate in our models. 
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Figure 25 - AML cell line show higher rate of glutaminolysis compared to NPBLs. Normal or activated 
NPBLs, OCI-AML3 and U937 were cultured for 24h. NH4 levels on culture medium were determined as 
indicated in the method section. 
 
We then measured ammonia levels after 24h of AOA exposure. In OCI-AML3 cells, we found a 
trend toward a dose-dependent inhibition of glutaminolysis, although not statistically significant 
(Fig 26). Minor effects were seen in AOA-exposed normal or activated NPBLs (fig 27a, b). 
 
Figure 26 – AOA inhibits glutaminolysis in AML cell lines. OCI-AML3 cells were exposed to the indicated 
concentrations of AOA for 24h. NH4 levels on culture medium were determined as indicated in the 
method section. 
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Figure 27 – AOA exposure induces only minor effects on NPBLs’ glutaminolytic rate.  Resting (a) or PHA-
activated (b) NPBLs were exposed to the indicated concentrations of AOA for 24h. NH4 levels on culture 
medium were determined as indicated in the method section. 
 
Moreover, we evaluated the effect of long-term AOA exposure on cell growth. All cell lines 
tested showed a marked sensitivity to this compound, with a dose- and time-dependent 
reduction of cell count (fig. 28) 
 
 
Figure 28 - AOA induces a dose- and time-dependent cell growth reduction on AML cell lines. OCI-AML2 
(a) and MOLM13 (b) were exposed to the indicated concentrations of AOA. Cell counts and viability were 
assessed at the times indicated by Trypan blue exclusion counting. 
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The AOA-induced cell growth reduction was associated to an apoptotic process, as 
demonstrated from Annexin V analysis (fig 29). Table 3 reports the IC50, calculated after 72h of 
AOA exposure, for our cell line panel, with OCI-AML3 being the most sensitive (136.9µM) and 
HL60 the least (978,6µM). This HL60 mild sensitivity to AOA, together with the resistance to 
glycolysis modulator DCA, suggests that this leukemia model has a peculiar metabolism, that 
diverge from the other cell lines tested, confirming previous observation from other groups 
[101]. 
 
 
Figure 29 – AOA exerts a dose- and time-dependent pro-apoptotic effect on AML cell lines. OCI-AML3 (a) 
and HL60 (b) cells were exposed to the indicated concentrations of AOA. Apoptosis induction was 
assessed by Annexin V/PI staining (see “Material and Methods” section). Percentage of Annexin V-positive 
cells is shown in the figure. 
 
 
 
 
 
 
 
Cell Line IC50 
U937 270,7 uM 
OCI-AML3 136,9 uM 
HL60 978,6 uM 
MOLM13 268,1 uM 
Table 3 - AOA induces apoptosis in AML cell lines. IC50 was calculated after 72h of DCA exposure  
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To evaluate the effects of this inhibitor on normal cells, we exposed normal and activated NPBLs 
to scalar concentrations of AOA. Results obtained demonstrated that AOA did not exert pro-
apoptotic effect in NPBLs (fig. 30). 
 
Figure 30 – AOA shows no effects on NPBLs. Normal (a) and activated (b) NPBLs were incubated with AOA 
for up to 72 hours. Apoptosis induction was assessed by Annexin V/PI staining (see “Material and 
Methods” section). Percentage of Annexin V-positive cells is shown in the figure. 
Finally, we evaluated the effect of AOA exposure on primary blasts from 8 AML patients (table 
2). 72h of AOA exposure exerted a statistically significant apoptotic effect, ranging from 25±4.9% 
(control) to 28.6±4.8% (100µM, p=0.04), 32.1±11.4% (500µM, p=0.03) and 35.7±13.5% (1000µM, 
p=0.01) (fig. 31) 
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Figure 31 - AOA induces a dose-dependent apoptosis in AML primary cells. AML primary cells were 
exposed to the indicated concentrations of AOA for 72h. Apoptosis induction was assessed by Annexin 
V/PI staining (see Methods section). Percentage of Annexin V-positive cells is shown in the figure. 
To our knowledge, this is the first report of AOA pro-apoptotic effects on AML cells. In line with 
recent results in literature, we show that glutamine is a fundamental substrate for AML cells. 
Bouscary’s group demonstrated that glutamine uptake, by l-ase administration, can be 
considered a promising target in AML treatment [96]. However, they reported the sudden 
insurgence of a resistance mechanism, through up-regulation of glutamine synthase, the enzyme 
responsible for its synthesis [96]. Thus, we propose a different approach, targeting the 
downstream process of glutamine incorporation in the TCA cycle, thus preventing its use as 
anaplerotic substrate for leukemic cells. Interesting results has been reported in AML with other 
glutaminase inhibitors, such as BPTES [85], Zaprinast [171], and a molecule developed by 
Calithera Biosciences (CA, USA), named CB-839 [172], which recently entered in phase I clinical 
trials (NCT02071927).  
Taken together, these evidences underline the role of glutamine in AML cell metabolism, and 
provide the rationale for targeting this metabolic process in AML treatment. 
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Chapter IV 
Targeting Fatty Acid Oxidation in Leukemia Cells: ST1326 
 
4.1 Introduction 
Recent studies have focused attention on the key role of fatty acid oxidation (FAO), as a way to 
produce ATP, NADPH and acetyl-CoA in neoplastic cells [173]. The carnitine palmitoyl transferase 
1a (CPT1a) catalyzes the first step of FAO, by loading long-chain fatty acyl-groups onto carnitine, 
transporting them through the mitochondrial membrane (fig 32). CPT1a has been previously 
demonstrated to interact with members of the apoptotic machinery, such as Bcl-2 [174] and t-
Bid [175], and its inhibition can cause an accumulation of the toxic metabolite palmitate, 
resulting in mitochondrial damage and cell death [105]. The inhibition of CPT1a has already been 
applied in leukemia with positive results [105] 
 
Figure 32 - Lipid transport across mitochondrial membrane and beta-oxidation, from [176] 
.  
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ST1326 is an aminocarnitine derivative characterized by a selective reversible inhibitory activity 
towards the liver isoform of the enzyme CPT-1a. ST1326 was initially selected by Sigma-Tau 
laboratories as a candidate for the oral therapy of diabetes and for the treatment and 
prevention of ketoacidosis [177], being the liver CPT1 inhibition considered an efficacious 
strategy in the therapy of diabetes [178].  
 
Figure 33 – Chemical structure of ST1326 (from 
www.http://chem.sis.nlm.nih.gov/chemidplus/rn/250694-07-6) 
 
Results recently reported by Pacilli and colleagues [179] demonstrated that the pharmacological 
inhibition of FAO by ST1326 strikingly impairs cancer cell survival and inhibits tumor cell 
proliferation in vitro and in vivo models of Burkitt’s lymphoma. Therefore, we aimed in this study 
to expand this approach, investigating the in vitro anti-leukemic activity of ST1326 on both 
human leukemia cell lines and primary cells obtained from patients with different 
haematological disease. 
 
4.2 Materials  
4.2.1 Reagents 
The CPT-1 inhibitor, ST1326, kindly provided by Sigma-Tau Pharmaceutical Industries S.p.A. Italy, 
was stored as dry powder at 0-4°C and dissolved in PBS immediately before use.  
4.2.2 Cell culture and primary samples 
Cell lines originating from hematological malignant disorders of myeloid (U937, KG-1, HL60, 
Hl60MTX, K562) and lymphoid (Raji, Jurkat, Molt4, CEM S, CEM R) origin, have been used as cell 
models. Cell lines cultured under standard conditions were harvested in log-phase growth for all 
experiments, washed and seeded with scalar concentrations of ST1326 (1 to 50μM). Wash out 
experiments were also performed by washing the cells exposed for 24-72h to ST1326 twice with 
PBS. 
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Normal mononuclear cells were obtained from peripheral blood (NPBLs) samples of volunteer 
donors. Normal CD34+ cells were obtained by immunomagnetic separation (Miltenyi Biotec, 
Bologna, Italy) from leukapheretic product of a normal volunteer (PBSC). PB and/or bone 
marrow (BM) aspirates samples were obtained from 24 leukemia patients (Table 4), who 
provided written informed consent, in accordance with regulations and protocols sanctioned by 
the Human Subjects Committee of Helsinki and approved by the Institutional Review Board of 
the Sapienza University of Rome. Cells were suspended in complete medium to a starting 
concentration of 1.0x106/mL and exposed to scalar concentration of ST1326 (1 to 50μM), and 
for selected experiments, to Etomoxir (5 to 50μM). 
 
4.3 Methods  
4.3.1 Cell cycle and apoptosis analysis 
Cell cycle distribution changes were evaluated using the Acridine Orange (AO) technique as 
previously described [180, 181]. The percentage of cells in the G0, G1, S, and G2M were 
determined by measuring simultaneously the DNA and RNA total cellular content. The 
percentage of apoptotic cells was measured based on the decreased stainability of apoptotic 
elements in DNA green fluorescence (sub-G1 peak on DNA-frequency histograms) coupled with 
a higher RNA red fluorescence (which is common to chromatin condensation) [180]; cell debris 
were excluded from the analysis on the basis of their forward light scatter properties. Cell-cycle 
distribution was analyzed using the ModFit LT software (Verity Software House, Topsham, ME).  
Induction of apoptosis was also assessed by measuring Annexin V binding to externalized 
phosphatidylserine, as previously described. Briefly, cells were washed twice with PBS and 
resuspended in binding buffer (10 mM Hepes/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2, Sigma 
Chemical Co.). FITC conjugated Annexin V (Roche Diagnostic Corp., Indianapolis, Indiana, USA) 
was added at a final concentration of 1μg/ml. The mixture was incubated at room temperature 
for 15 min in the dark prior to flow cytometry analysis. Membrane integrity was simultaneously 
assessed by PI (0.25μg/ml) exclusion. 
 
4.3.2 Mitochondrial Membrane Potential 
To measure loss mitochondrial membrane potential (ΔΨm), cells were loaded with 300nM 
Chloromethyl-X-Rosamine (CMXRos) and 100μM MitoTracker Green (MTGreen), (Molecular 
Probes®, Invitrogen, Eugene, OR) for 1 hour at 37°C. The ΔΨm was then assessed by measuring 
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CMXRos retention (red fluorescence) while simultaneously adjusting for mitochondrial mass 
(green fluorescence). 
 
4.3.3 Functional FAO Assay 
FAO rates were measured in real time by the XF24 Extracellular Flux Analyzer (Seahorse 
Bioscience, MA, USA). Cells were suspended in unbuffered DMEM medium supplemented with 
2.5mM glucose and 0.5mM L-carnitine (all from Sigma-Aldrich) adjusted to pH 7.35, transferred 
in Celltak (BD Bioscience) coated plates and incubated for 30 minutes at 37°C in a CO2-free 
incubator. ST1326 or Etomoxir (Sigma-Aldrich) were added 15 minutes before the assay to a final 
concentration of 50μM. BSA or BSA-Palmitate (Seahorse Bioscience, MA, USA) were added to 
each well just prior the assay, to a final concentration of 33 and 200μM, respectively. Oxygen 
Consumption Rates (OCR) were measured for basal state and following the sequential injection 
of oligomycin (1μM), FCCP (0.4μM), and a mix of Antimycin A (1μM) and Rotenone (1μM) (all 
from Seahorse Bioscience, MA, USA) in each well. After the assay, cells were detached and 
manually counted to assess cell number and viability. OCR data were normalized for cell 
number. 
4.3.4 Histomorphological analysis 
Mitochondria were stained by incubating cells with 500nM MitoTracker Red CMXRos (Molecular 
Probes, Milan, Italy) in complete medium for 30 min, followed by 30 min in complete medium 
without MitoTracker. For CPT1A staining, cells were fixed by using 3% paraformaldehyde in 
100mM phosphate buffer and 60mM sucrose for 15 min at room temperature (RT), and then 
washed twice in PBS. Cells were permeabilized with 1% (w/v) Triton X-100 in PBS and 20 mM 
glycine for 10 min at RT and then washed twice in PBS. Before the addition of the CPT1A 
antibody, cells were incubated with PBS containing 10% pre-immune goat serum at RT for 30 
min. Afterwards, cells were stained with the rabbit anti-CPT1A polyclonal antibody (Novus 
Biological, Milan, Italy) for 1h at 37°C following the manufacturer’s procedure. After washing 
twice in PBS/20mM glycine, cells were incubated with goat anti-rabbit Alexa Fluor® 594 
(Molecular Probes) for 1h at 37°C, and then washed twice in PBS. Fluorescent staining was 
viewed on a Zeiss LSM 710 confocal laser-scanning microscope equipped with 63x objective at 
excitation wavelengths of 561 nm for Alexa Fluor 594. 
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4.4 Results & discussion 
We initially confirmed in a collaborative study the presence of the target, CPT1a, in Raji cells by 
immunofluorescence analysis that demonstrated the mitochondrial localization of CPT1a (Fig. 
34, courtesy of G. Peluso).   
 
Figure 34– Leukemia cells express CPT1 isoform A. Raji cells were stained as described in the method 
section 
Then, we documented that ST1326 was effective in inducing FAO inhibition as demonstrated by 
real-time metabolic analysis. The exposure for 75 minutes to ST1326 at 50μM caused a 
significant impairment of fatty acid (FA)-based maximal respiratory capacity: U937 cells in fact 
showed a 45.2% (p<0.001) reduction of this parameter when compared to palmitate-only 
control, while 50μM of Etomoxir induced only minor effects (4% reduction) (Figure 35).  
 
Figure 35 - ST1326 induces FAO decrease in AML cells. Time course of a FAO experiment on U937 cells, 
exposed to ST1326 or etomoxir 
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Moreover, ST1326 affected both basal and maximal FA-based respiratory capacity in HL60-MX2 
cells (Figure 36a): the reduction was 82% (p<0.01) and 67.2% (p=0.01), respectively, when 
compared to palmitate-only condition. The effectiveness of ST1326 (50μM) in inhibiting FAO 
process was confirmed on primary acute myeloid leukemia (AML) cells (Figure 36b): an 
impairment of FA-based mitochondrial activity was obtained on both basal (-59.4%, p<0.01) and 
maximal respiration (-53.9%, p=0.037). 
 
 
 
Figure 36 - ST1326 induces FAO decrease in AML cells. Basal and maximal respiration rates for (a) HL60-
MX2 cells and (b) AML primary blasts exposed to ST1326. Basal rates are calculated at 19 minutes from 
the beginning of the experiment (34 minutes of ST1326 exposure); maximal respiration rates are 
calculated after the electron transport chain-accelerator (FCCP) injection, 55 minutes after the beginning 
of the experiment (70 minutes of ST1326 exposure). 
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We then analyzed anti-proliferative and cytotoxic activity of ST1326 demonstrating that the 
CPT1a inhibitor induced dose- and time-dependent cell growth arrest, cell cycle modulation and 
apoptosis (Figure 37, 38, 39). In particular, a marked depletion of the S phase, associated with an 
increase in both G2M phase and sub-G0/1 peak, was documented after 24 hours of exposure to 
50μM of ST1326. The same effects occurred also at low ST1326 concentrations over longer times 
of exposure (Figure 39). Etomoxir failed to reproduce similar significant results (Figure 38). The 
cytotoxic activity of the molecule was also confirmed by using Annexin V (data not shown).  
 
Figure 37 - ST1326 induces cell growth arrest in dose and time-dependent fashion in hematopoietic cell 
lines with different ontogenesis. Dose-response growth curves: several hematopoietic cell lines were 
exposed to increasing concentrations of ST1326 for the indicated periods of time. Cell counts and viability 
were then assessed by Trypan blue exclusion counting. 
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Figure 38 - ST1326 induces a dose and time-dependent cell cycle modulation and apoptosis induction in 
U937 cells. U937 cells were exposed to the indicated concentrations of ST1326 or vehicle control for up to 
72 h. Distribution of cells in the different phases of cell cycle and in the sub-G0/1 peak was assessed by 
Acridine orange DNA/RNA staining as described in methods section. DNA histograms show results of one 
representative experiment performed on U937 cells. 
 
 
Figure 39 - ST1326 induces a higher apoptotic effect compared to Etomoxir in hematopoietic cell lines. 
HL60 (a) and MOLT4 (b) were treated with ST1326 (1 to 50μM) or with Etomoxir (1 to 50μM) for up to 72 
hours. At the indicated time points, cells were harvested, counted by Trypan blue dye-exclusion under a 
light microscope, and distribution of cells in the different phases of cell cycle was assessed as described in 
methods. Percentages of cells in subG0/1 peak are shown in the figure.  
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Figure 40 - ST1326 induces ΔΨm decrease in hematopoietic cell lines. HL-60/MX2 (a) and MOLT4 (b) 
were grown in the absence or presence of scalar concentrations of ST1326 for up to 72 h. Loss of ΔΨm 
was determined at the indicated time points by monitoring CMXRos uptake. 
 
The experiments of wash-out of the drug carried on the U937 cell line have shown that ST1326, 
when administered for 24 hours at a concentration of 50μM, exerted an irreversible cytotoxic 
activity (Fig. 41a). In contrast ST1326 displayed reversible drug effects on cell cycle and 
apoptosis at the doses of 5, 10 and 20μM. In fact, cell cycles rate was re-established after 10 
days from the drug removal at 20μM. Prolonged exposure (72 hours) of the ST1326 
concentration exerted an irreversible cytotoxic activity also at 20μM (Fig. 41b). 
 
 
Figure 41 - ST1326 exerts an irreversible cytotoxic effect at the higher concentrations in U937 cell. U937 
cells were exposed to the indicated concentrations of ST1326. The compound was removed after (a) 24 h 
and (b) 72h, the U937 cells were then re-suspended in fresh medium. Cell counts and viability were then 
assessed at the times indicated by Trypan blue exclusion counting. 
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The results obtained from the analysis of AML samples indicated that ST1326 exerts 
antiproliferative and cytotoxic activity in a dose- and time-dependent fashion in all (12/12) 
samples studied (Figure 42a). Induction of apoptosis was associated with a significant reduction 
of cell counts (Figure 42b). ST1326 induced a significant increase in apoptosis also in samples 
from two relapsed AML: Annexin V+ cells increased from 21.18%±7.75 to 25.23%±6.53 (p=n.s.), 
30.20%±3.27 (p=n.s.), 73.09%±4.11 (p=0.00018) in the presence of 10, 20, 50μM ST1326, 
respectively. 
A time and dose-dependent increase in the levels of apoptosis was observed in 5/5 samples 
from acute lymphoblastic leukemia (B-ALL) (Figure 42c) and in 6/6 samples from chronic 
lymphoblastic leukemia (CLL) (Figure 42e) analyzed after exposure to ST1326. As already 
observed for AML samples, the apoptosis increase was associated with a significant (at 50μM) 
cell count reduction (Figure 42d, f). The sample obtained from a relapsed B-ALL patient was 
equally sensitive to ST1326 cytotoxic activity. 
 
Table 4 - Patient population 
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Figure 42 - ST1326 induces a dose and time-dependent apoptosis in primary cells from hematopoietic 
disease. AML (a/b) ALL (c/d) and CLL (e/f) primary cells were exposed to the indicated concentrations of 
ST1326. (a, c, e) Apoptosis induction was assessed by Annexin V/PI staining (see “Material and Methods” 
section). Percentage of Annexin V-positive cells and Annexin V-positive/PI cells are shown in the figure. (b, 
d, f) Cell counts and viability were assessed at the times indicated by Trypan blue exclusion counting. 
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With the aim of analyze the activity of ST1326 on normal hematopoietic cells, NPBLs obtained 
from healthy donors have been studied in liquid culture +/- ST1326 in the absence and in the 
presence of a proliferative stimulus (PHA). The results showed that ST1326 induced an increase 
in the levels of apoptosis only after stimulation with PHA at a dose of 50μM after 72 hours of 
culture (Fig. 43b). No cytotoxic effects were detected on resting NPBLs (Fig. 43a). Moreover, we 
tested the effects of ST1326 exposure on PBSCs from a normal donor demonstrating the 
absence of significant changes in the viability of CD34+ cells, as reported in figure 44. 
 
Figure 43 - ST1326 induces apoptotic effect only at the highest concentration in PHA-stimulated normal 
PBL. Normal and activated NPBLs were incubated with ST1326 for up to 72 hours. Percentages of cells in 
subG0/1 peak, assessed as described in methods section, are shown in the figure. 
 
Figure 44 - ST1326 has no effect on PBSCs. Normal PBSCs were incubated with ST1326 for up to 72 hours. 
Percentages of viable CD34+ cells are shown in the figure, assuming the viability of untreated CD34+ as 
100%. 
So far, lipid metabolism in cancer cells has been investigated mainly from the anabolic 
perspective, being Fatty Acid Synthase (FASN) overexpressed in many cancers [182]. Conversely, 
the importance of FAO in cancer cell bioenergetic balance has been poorly established. Our 
results agree with the previously data reported by Samudio and colleagues [105], reinforcing the 
idea that β-oxidation represents a crucial metabolic pathway for leukemic cells, not only for 
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energy production but also for controlling cell growth, survival and chemoresistance. Moreover, 
these observations have been strengthened by following works on other haematological 
malignancies, such as MM [107], Diffuse Large B Cell Lymphoma [183] and CLL [184]. In 
particular, Tung S et al. [184] suggested that FAO plays a role in resistance of CLL to 
glucocorticoids and that the co-administration of glucocorticoids and FAO inhibitor may 
overcome this resistance. 
Taken together, these findings emphasize the role (i) of FAO as a potential target for leukemia 
treatment and (ii) of ST1326 as a promising agent able to effectively inhibit FAO on leukemia 
cells, leading to cell growth reduction and apoptosis. 
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Chapter V 
Conclusions 
Despite the recent advances in understanding the biology of leukemia cells, introduced by the 
use of next generation techniques, the arising of chemoresistance up front or, more frequently, 
during the course of the disease, remains “the problem” to be solved in order to improve the 
outcome, especially of adult and elderly patients. 
In fact, the overall long term survival rate is, in adult ALL patients, less than 35-45% [185]. 
Similarly, among the adult patients affected by AML, only 40% remains in remission 5 years after 
diagnosis [186].  
The use of novel targeted therapies, so far entered as standard treatment only in few selected 
diseases, did not erase the later onset of resistance to these agents [187]. 
These observations represent the background of our studies addressed at searching for 
therapeutic agents, targeted toward novel specific and pathogenetic alterations of leukemia 
cells. 
The metabolic reprogramming is currently recognized as one of the main feature that 
differentiates cancer cells from normal cells [7]. Thus, it represents a promising target for 
innovative treatment. The reason for the interest lies in the fact that metabolism is downstream 
of genomic and proteomic alterations. So, it constitutes a sort of a “bottleneck” in which 
activated oncogenes and aberrant signaling converge [188]. 
Progress has been made, with several clinical trials exploiting this metabolism targeted-approach 
in solid tumors (table 5). However, to our knowledge, only few of these have been recently 
opened in hematological malignancies: Metformin in CLL (NCT01750567), Metformin in 
combination with Temsirolimus in Lymphoma (NCT00659568), CPI-613 (a mitochondrial 
inhibitor) in combination with bendamustine in T-cell Lymphoma (NCT02168140) and CB-839 
(glutaminase inhibitor) in Acute Leukemias (NCT02071927) 
Our work, together with others, attempts to shed light on preclinical features of leukemia cells, 
by targeting the three major catabolic pathways that contributes to cellular bioenergetic status, 
glycolysis, glutaminolysis and FAO.  
DCA is directed at the most characterized metabolic alteration of tumor cells, the aerobic 
glycolysis. Our results suggest that it is possible to reverse this alteration, forcing leukemia cells 
to adopt a metabolism that cannot be sustained by them, inducing ROS accumulation and 
apoptosis. Indeed, resistance showed by some cell lines suggests that at least some AML subtype 
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may not respond to this kind of therapy. Nevertheless, results from DCA-exposed primary blasts 
show high rates of apoptosis in all patients included in the study, reaffirming the potentiality of 
this molecule. 
 
 
Table 5 – Metabolic inhibitors in clinical trials, from [189] 
Glutaminolysis inhibition, by AOA, directly targets an anaplerotic substrate, able to provide 
energy, nitrogen, and redox buffering to cancer cells. TCA cycle is the central core of cellular 
metabolism, acting as energy source and biosynthetic intermediate provider. A failed entrance 
into TCA cycle of glutamine may determine in leukemia cells an inability in keeping this process 
active, depriving them of such a fundamental bioenergetic hub. Our work indicates that this 
approach can be feasible. Moreover, other author reported [85, 171] that glutaminolysis 
inhibition can be particularly effective in the IDH-mutated AML patient subclass. 
Targeting FAO represents an innovative approach among this strategy, being so far little 
investigated in both solid tumors and hematological malignancies. However, evidences are 
accumulating stating the importance of this process in the bioenergetic balance of cancer cells, 
especially in leukemias [105]. FAO process can be the factor explaining the observed link 
between obesity and cancer incidence [190]. Thus far, the mostly used inhibitor, etomoxir, failed 
to show the selectivity required to target cancer cells [179]. Moreover, it has been reported that 
etomoxir is active only against long-chain fatty acid oxidation [191].  
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Results obtained by Pacilli et al., using the novel FAO inhibitor ST1326, proved the effectiveness 
of this compound against both long and short-chain fatty acid oxidation [179]. Additionally, it 
demonstrated a selective activity against the CPT1a isoform, expressed by lymphoblastoid cells 
[179]. In our models the same molecule, ST1326, proved to induce a pro-apoptotic effect in 
AML, in the low micromolar range, and at 50µM in ALL and in CLL while etomoxir failed to show 
any activity.  
In conclusion, these results prompt further studies aimed to characterize metabolic features 
associated with different hematological diseases, and to establish correlations between clinical, 
immunophenotype, molecular genetic, signaling features and metabolic alteration. Hence, it 
would be possible to select for metabolic inhibitors effective, alone or in combination with 
standard therapy, in the hematological malignancies characterized by the correspondent 
metabolic alteration. 
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